Meeting
2015 ASCO Annual Meeting
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).
Authors
David Malka
Gustave Roussy, Villejuif, France
David Malka , Florence Castan , Eric Francois , Olivier Bouche Sr., Jaafar Bennouna , Francois Ghiringhelli , Christelle De La Fouchardiere , Christophe Borg , Emmanuelle Samalin , Jean Baptiste Bachet , Jean-Luc Raoul , Frédérique Cvitkovic , Laurent Miglianico , Leila Bengrine-Lefevre , Laetitia Dahan , Cedric Lecaille , Thomas Aparicio , Herve Perrier , Sophie Gourgou , Julien Taïeb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
2009-012797-12
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4013)
DOI
10.1200/jco.2015.33.15_suppl.4013
Abstract #
4013
Poster Bd #
122
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.
First Author: D. Malka
Poster
2021 ASCO Annual Meeting
Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.
First Author: Shen Zhao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki
Poster
2023 ASCO Annual Meeting
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
First Author: Kohei Shitara